Sentences with phrase «overall median survival»

Some patients given both treatments lived significantly longer (years) than expected, while the overall median survival increased by 59 % (2.6 months).

She suggests that one - and two - year survival data may provide more information about the effectiveness of these drugs than overall median survival rates.

Without resection, overall median survival is four to six months with an estimated five - year survival rate of 0.4 percent to 5 percent.

Not exact matches

«Patients who respond to immunotherapy tend to continue their responses for long durations, and these lengthier responses are cut off in calculations of median overall survival,» she says.

Brahmer emphasizes that the relatively small increase in median survival time with the use of the new immunotherapy drugs may be somewhat misleading in terms of overall impact of the medicines.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

A follow - up of the 48 patients who were evaluable at a median time of 24 months indicated no statistical differences between the two groups in terms of overall or progression - free survival.

Now, at 5.3 years median follow up, the impact on overall survival is reported and represents a 28 % reduction of the relative risk of death (hazard ratio 0.72, p = 0.001).

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

In the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocol.

Study results show that patients with prior knowledge of MGUS had better overall survival (median 2.8 years) than patients with MM who didn't know when they had MGUS (median survival 2.1 years), although patients with prior knowledge of their MGUS status had more coexisting illnesses.

The median progression - free survival was 2.5 months and the median overall survival was 26.1 months.

After a median follow up exceeding 16 years, researchers found that overall, survival did not differ between the two groups of men.

Classified this way, grade 2 and 3 oligodendrogliomas and astrocytomas demonstrate median overall patient survival ranging from three to ten years.

As of April 2015, with a median follow up of 30.1 months, the media progression free survival was 19.1 months and the median overall survival had increased to 32.1 months.

There was no statistically significant difference in median overall survival.

«Similarly 71 drugs approved by the FDA from 2002 to 2014 for solid tumours have resulted in median gains in progression - free and overall survival of only 2.5 and 2.1 months, respectively,» he says adding, «Also, only 42 per cent met the American Society of Clinical Oncology Cancer Research Committee's criteria for meaningful results for patients.»

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

Median overall survival was 10.4 months for SRS alone and 7.4 months for SRS plus WBRT.

The researchers found that patients capable of holding their breath over the course of treatment had a 90 percent disease - free survival, and a 96 percent overall survival, with a median reduction in radiation dose to the heart of 62 percent.

The study is ongoing, accruing patients rapidly, and CT scan data are available on 27 of these patients, of whom 18 had a confirmed response to the treatment, giving an overall response rate of 67 % and a median progression - free survival of 10.4 months.

Mean progression - free survival was 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

Statistical analysis was used to determine Overall Survival (OS), Disease Specific Survival (DSS) and PSA Failure rates (PSAF), and the median follow - up was more than 11 years.

With a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Those with mutations had a median overall survival of 19.1 months, compared with 9.3 months in those with EGFR mutations.

After a median follow - up of 42 months from diagnosis, the 3 - year PFS rate was 66 %, and overall survival was 89 %.

With a median follow up of 22 months, the 2 - year overall survival probability was 60.7 % in patients aged 65 years or under and 55.6 % in patients aged over 65 years (P = 0.40).

Regardless of the type of therapy, the prognosis has been a dismal reported median overall survival of 12 - 16 months and high rate of relapse within 1 year [1 - 3].

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

The median overall survival for previously untreated patients was 18.6 months.

Retrospective case reports suggest that adults may benefit from consolidation with allogeneic HSCT during their first CR following chemotherapy with one study observing a median overall survival of 38.5 months [5].

Overall response rate among the 47 previously treated was 68 %, and the median overall survival was 11.25 Overall response rate among the 47 previously treated was 68 %, and the median overall survival was 11.25 overall survival was 11.25 months.

The median progression - free survival was 4.3 months, and median overall survival was 6.4 months.

A prespecified biomarker analysis found that patients with pSTAT3 - positive tumors had significantly improved overall survival when treated with napabucasin compared with placebo (median, 5.1 vs 3.0 months; hazard ratio, 0.41; 95 % CI, 0.23 — 0.73; P =.0025).

The median overall survival for napabucasin was 4.4 months compared with 4.8 months for placebo.

The median overall survival was 12.5 months, and the 12 - month overall survival rate was 58 %.

Median overall survival was not reached.

In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009).

Renal impairment is associated with poor prognosis and short survival duration, with a median overall survival of less than 2 years.

The treatment resulted in a median overall survival (OS) of longer than 3 years in both arms of the trial (median OS, 38.2 months for irradiation vs 36.6 months for nonmyeloablating chemotherapy alone; hazard ratio, 1.11 [95 % CI, 0.65 — 1.91]-RRB-.

The median overall survival of patients in the Phase 1 resection injection study, where Toca 511 was injected into the wall of the resection cavity after removal of the tumor, exceeds historical controls across a variety of previously reported clinical trials.

For newly diagnosed GBM patients treated with current standard of care, median progression free survival is just 6.9 months, and median overall survival is 14.6 months.

The approval came on the heels of the first phase III clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival of 10.1 months, versus 6.4 months in the control group.